Cytodyn (CYDY) Osake Kurssi

Cytodyn Inc is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Cytodyn Inc in the market are pharmaceutical companies such as Gilead Sciences, Inc., Bristol-Myers Squibb Company, and Merck & Co., Inc. These companies also focus on the development and commercialization of innovative therapeutics, similar to Cytodyn. However, Cytodyn differentiates itself through its unique drug candidates, including Leronlimab, which targets multiple indications such as HIV, cancer, and immunological disorders. Despite the competition, Cytodyn strives to carve its niche in the pharmaceutical industry by delivering groundbreaking therapies with the potential to revolutionize patient care and improve outcomes.

Cytodyn Inc is a biotechnology company with a history dating back to 2002. It specializes in the development of innovative therapies for patients with unmet medical needs, particularly in the areas of cancer, HIV, and immunology. The company's focus lies in the development of monoclonal antibody-based treatments that aim to improve patients' quality of life. Cytodyn Inc has made significant strides in its research and development efforts, consistently working towards bringing potentially life-saving treatments to market. With a dedicated team and a strong commitment to scientific advancements, Cytodyn Inc continues to push the boundaries of biotechnology and deliver promising outcomes for patients worldwide.

Cytodyn Inc has achieved several significant milestones. The company successfully developed PRO 140, a monoclonal antibody targeting CCR5, which received Fast Track designation from the FDA for HIV-infected patients. Additionally, Cytodyn obtained positive results from pivotal Phase 3 trials of PRO 140 for HIV treatment, showing superior efficacy and safety compared to existing therapies. The company has also explored the therapeutic potential of PRO 140 in different indications, including metastatic triple-negative breast cancer and graft-versus-host disease. These achievements highlight Cytodyn Inc's commitment to pioneering innovative treatments that address critical medical needs.

Cytodyn Inc is primarily present in the United States.

Cytodyn Inc is a biotechnology company dedicated to revolutionizing the treatment landscape for various diseases. Focused on innovative therapies, Cytodyn prioritizes patient well-being, scientific excellence, and ethical conduct. The company's corporate philosophy centers around developing cutting-edge solutions that address unmet medical needs and improve the quality of patients' lives. With an unwavering commitment to research and development, Cytodyn strives to foster collaborations, enhance healthcare accessibility, and drive global healthcare improvements. By adhering to its core values of integrity, innovation, and compassion, Cytodyn Inc continuously seeks to make a positive impact in the field of biotechnology.

6 analyytikkoa arvioi tällä hetkellä Cytodyn-osaketta: 0 suosittaa ostoa, 3 pitoa ja 3 myyntiä.

Cytodyn Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Cytodyn-osake noteerataan hintaan 0,18 EUR (0,20 USD).

Cytodyn-osake (CYDY) on listattuna 3 pörssissä, muun muassa: München (296.MU).

Cytodyn Inc is an international biopharmaceutical company specializing in the development of innovative therapies and technologies in the field of immunotherapy. The company was founded in 2002 and is headquartered in Vancouver, Canada. Cytodyn Inc's business activities are divided into three areas: research and development, clinical trials, and marketing. In the research and development area, the company focuses on developing biotechnology products for the treatment of infectious diseases, autoimmune diseases, and cancer. These are highly specialized therapies based on strengthening the immune system. One important product of the company is the HIV blocker program "PRO 140" - a monoclonal antibody that can offer HIV-infected patients a rare but life-changing chance for viral suppression. In addition, the company is working on other innovative therapy approaches, such as the treatment of graft-versus-host diseases (GvHD), which occur in many patients who have undergone stem cell transplantation. In the context of clinical trials, the company tests its products and technologies in collaboration with leading universities and research institutions worldwide. It relies on strict quality controls and compliance with all regulatory requirements. The goal is to prove the safety and efficacy of the therapies and bring them to market readiness. Cytodyn Inc's marketing activities are carried out through a wide range of distribution and marketing channels. The company collaborates with leading distribution partners and medical facilities worldwide to make its products available to customers. It also focuses on targeted marketing to continuously expand the awareness of its product range. Cytodyn Inc. follows a growth model that promotes collaborative partnerships in the areas of research, development, and marketing. The company works with various partners to accelerate the development of new therapies and technologies and to capitalize on international business opportunities. The goal is to fully harness the potential of immunotherapy and make a significant contribution to improving healthcare worldwide. To optimize search results, this text is SEO-optimized and contains targeted keywords.

Liikevaihtoa ei voida laskea Cytodyn:lle tällä hetkellä.

voitto Cytodyn on −42,70 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Cytodyn:n hinta-voitto-suhde (P/E) on tällä hetkellä −6,43. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Cytodyn-osakkeen arvostusta.

P/S-suhdetta ei voida laskea Cytodyn:lle tällä hetkellä.

Cytodyn:n Eulpool-laatuscore on 1/10.

Cytodyn:n ISIN on US23283M1018. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Cytodyn:n WKN on A0YHA5. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Cytodyn:n ticker on CYDY. Tämä pörssinoteeraus käytetään Cytodyn-osakkeiden kauppaan pörssissä.